M. Chaudhry

Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.

J. Storek, N. Bahlis, N. Bahlis, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.

M. Horowitz, K. Ballen, C. Bredeson, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.

J. Storek, P. Duggan, N. Bahlis, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.

A. Magliocco, F. Naveed, J. Storek, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

W. Irish, J. Storek, P. Duggan, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.

B. Andersson, F. Naveed, J. Storek, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD

A. Lyon, J. Storek, J. Russell, 2013, Bone Marrow Transplantation.

Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.

J. Storek, P. Duggan, N. Bahlis, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG

J. Storek, P. Duggan, N. Bahlis, 2011, Bone Marrow Transplantation.

Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis

J. Szer, I. Lewis, J. Storek, 2015, Bone Marrow Transplantation.

Investigations of Murine Embryonic Stem Cell Maintenance by Analyses of Culture Variables and Gene Expression

C. Eaves, J. Bryan, R. Humphries, 2007 .